Onesource Specialty Pharma Limited has informed the Exchange about Copy of Newspaper Publication
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma has re-submitted its newspaper advertisement of Q4 and FY25 financial results to the stock exchanges after the original Lokmat (regional language) ad was truncated and its QR code was omitted. This is a procedural re-intimation and not new financial information, as the results were originally disclosed on May 7, 2025. The underlying results show strong growth: consolidated total income from operations rose to about ₹175,406.87 lakhs in Q4 FY25 from ~₹126,507.84 lakhs in Q4 FY24 (~39% growth). Consolidated net profit after tax for Q4 FY25 stood at ₹20,702.53 lakhs (vs ₹16,403.23 lakhs in Q4 FY24), while full-year FY25 PAT was ₹75,124.61 lakhs versus ₹61,189.65 lakhs in FY24 (~23% growth). Standalone FY25 PAT was ₹73,720.19 lakhs. Diluted EPS for FY25 (consolidated) was around ₹13.97. The board approved the results on May 5, 2025 and the NCLT scheme with an appointed date of April 1, 2024 is now reflected in these consolidated numbers.
This is a compliance re-submission with no new material information, so the immediate stock reaction should be minimal. However, the underlying financials point to robust revenue and profit growth, which is a positive signal for shareholders. Investors should watch for any further clarity on the impact of the NCLT scheme and the reason Lokmat's earlier publication was truncated.